Final results from Phase III PRIMROSE program of linzagolix for the treatment of uterine fibroids

Linzagolix is a novel, once daily GnRH receptor antagonist. The final 76-week results from PRIMROSE 1 show sustained post-treatment effects and evidence of BMD recovery following 52 weeks of treatment.

Source:

Biospace Inc.